Organon & Co. (LON:0A9W)

Market Cap	1.86B
Revenue (ttm)	4.87B
Net Income (ttm)	580.49M
Shares Out	n/a
EPS (ttm)	2.23
PE Ratio	3.20
Forward PE	2.52
Dividend	0.67 (6.72%)
Ex-Dividend Date	May 12, 2025

Volume	855
Average Volume	4,048
Open	9.81
Previous Close	9.80
Day's Range	9.56 - 9.81
52-Week Range	8.05 - 22.88
Beta	n/a
RSI	44.96
Earnings Date	Aug 7, 2025

About Organon & Co.

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 10,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A9W

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Financial numbers in USD